Introduction
============

Pancreatic cancer is one of the most prevalent and lethal malignancies worldwide ([@b1-etm-0-0-7619]). Although substantial progress has been made in adjuvant and neo-adjuvant chemotherapies during previous decades, pancreatectomy remains the most effective treatment, notably for early stage pancreatic cancer cases. Despite this, a previous study demonstrated that only 20% of patients present with localized and non-metastatic disease, and are therefore suitable for initial resection ([@b2-etm-0-0-7619]). Due to its specific tumor biology, pancreatic cancer is characterized with early recurrence and metastasis and resistance to chemotherapy and radiotherapy. The 5-year overall survival rate is \<5% ([@b3-etm-0-0-7619]). Therefore, an improved understanding of the underlying mechanism of pancreatic cancer is required for the development of effective therapy and the improvement of patient survival.

Previously, the development of high throughout sequencing has resulted in the production of numerous gene expression profiles of neoplasms that are freely available via the Gene Expression Omnibus (GEO) database ([@b4-etm-0-0-7619]). Based on these data, the different aspects of the mechanism of pancreatic neoplasm development and the resistance to chemotherapy may be investigated. However, only a small part of these data has been used, and the majority of them have only been deposited. Using a bioinformatic analysis, these data may be re-analysed and used to provide valuable information for subsequent investigation. During the re-analysis process, differentially expressed genes (DEGs) are initially identified, and subsequently the functions and pathways of the genes involved are investigated. Several studies performed in pancreatic cancer have been performed previously ([@b5-etm-0-0-7619],[@b6-etm-0-0-7619]). Although the majority of these studies only focused on the identification of the most significant genes, the tumor and normal tissues were not paired in those analyses. Therefore, in the present study, three GEO datasets were selected, which contained paired tumor tissues and corresponding normal tissues, and the microarray data was analysed. The analysis led to the identification of the DEGs, and Gene Ontology (GO) and pathway enrichment analysis were subsequently performed to explore the biological functions and pathways of these genes. Furthermore, a protein-protein interaction (PPI) network was constructed and a module analysis was performed to explore the hub genes in pancreatic cancer. The present study may provide novel insights into the understanding of the mechanism of pancreatic cancer formation and its corresponding hub genes, and the pathways involved may serve as potential targets for the treatment of this cancer type.

Materials and methods
=====================

### Data source

The microarray data for the investigation of pancreatic cancer were downloaded from the GEO datasets ([www.ncbi.nlm.nih.gov/geo](www.ncbi.nlm.nih.gov/geo)) as follows: GSE15471, GSE16515 and GSE28735. The gene expression profiles of GSE15471 and GSE16515 were obtained using the GPL570 platform, and GSE28735 was obtained using the GPL6244 platform. GSE15471 and GSE28735 included 36 and 45 pairs of tumor and corresponding normal tissues, respectively. GSE16515 consisted of 36 tumor and 16 normal tissues. A total of 16 pairs of tissues were selected for subsequent analysis.

### DEG identification

DEGs between tumor and normal tissue samples were identified using the online analysis tool GEO2R ([www.ncbi.nlm.nih.gov/geo/geo2r](www.ncbi.nlm.nih.gov/geo/geo2r)), and the results were saved as a .txt format. The cut-off criteria for DEG identification were defined as adjusted P\<0.05 and \|log fold change (FC)\|\>1. Subsequently, the DEGs of the three GEO datasets were processed to generate a Venn diagram using an online resource (bioinformatics.psb.ugent.be/webtools/Venn).

### Gene Ontology (GO) and pathway enrichment analysis

To explore the primary functions and pathways of the DEGs involved, the Database for Annotation, Visualization and Integrated Discovery (DAVID; version 6.8; [david.ncifcrf.gov](david.ncifcrf.gov)) and the Panther ([www.pantherdb.org](www.pantherdb.org)) databases were employed to perform GO analysis. The Kyoto Encyclopedia of Genes and Genomes ([@b7-etm-0-0-7619]), and the Reactome pathway enrichment analysis were used for the pathway enrichment analysis ([@b8-etm-0-0-7619]--[@b10-etm-0-0-7619]). P\<0.05 and a DEG count ≥2 were set as criteria.

### PPI network construction and module analysis

The Search Tool for the Retrieval of Interacting Genes (STRING; [string-db.org](string-db.org)) was used to build a PPI network, and subsequently the network was visualized using Cytoscape v3.6.1 software ([@b11-etm-0-0-7619]). The cut-off criterion for the PPI network was a combined score \>0.4, and the hub genes were defined by a node degree \>10. The modules of the PPI network were calculated using the Molecular Complex Detection (MCODE) plug-in of Cytoscape with default parameters. Subsequently, the hub genes in high-scored modules (degree cut-off=2, node score cut-off=0.2) were selected for additional GO and pathway enrichment analyses.

Results
=======

### Identification of DEGs in pancreatic cancer

Gene expression profiles from three pancreatic cancer GEO datasets were analysed. Based on the cut-off criteria, 1,666, 1,501 and 412 DEGs were extracted from the GSE15471, GSE16515 and GSE28735 datasets, respectively. Subsequently, 226 DEGs were identified ([Fig. 1](#f1-etm-0-0-7619){ref-type="fig"}) by integrated bioinformatics analysis, including 179 upregulated and 47 downregulated DEGs ([Table I](#tI-etm-0-0-7619){ref-type="table"}).

### GO analysis of DEGs in pancreatic cancer

Candidate DEGs function enrichment analysis was conducted with DAVID and Panther software. The functions of the DEGs were classified into three groups as follows: 'Cellular Component'; 'Molecular Function'; and 'Biological Process' ([Fig. 2](#f2-etm-0-0-7619){ref-type="fig"}). DEGs were primarily involved in binding and catalytic activity with regard to the 'Molecular Function' group, cellular and metabolic processes with regard to the 'Biological Process' group, and cell membrane with regard to the 'Cellular Component' group. Furthermore, the top 30 GO terms of these DEGs ([Fig. 3](#f3-etm-0-0-7619){ref-type="fig"}), and the top 10 GO terms of the upregulated and downregulated DEGs were classified ([Table II](#tII-etm-0-0-7619){ref-type="table"}). The upregulated DEGs that were primarily enriched were associated with extracellular matrix (ECM) organisation, cell adhesion, collagen catabolic process and ECM disassembly in the 'Biological Process' group, whereas with regard to the 'Cellular Component' group ECM, extracellular space, extracellular region and extracellular exosome formation were the primary processes identified. The downregulated DEGs that were primarily enriched were associated with reactive oxygen species, metabolic processes, proteolysis and cellular response to starvation in the 'Biological Process' group. The enriched downregulated DEGs were also associated with extracellular exosome formation, extracellular space, integral component of plasma membrane and extracellular region with regard to the 'Cellular Component' group. These results indicated that the majority of DEGs were significantly enriched in processes, including extracellular exosome formation, ECM, ECM organisation, extracellular space and extracellular region.

### Pathway enrichment analysis of DEGs in pancreatic cancer

The DEG signaling pathway enrichment was performed with DAVID. The 30 significantly enriched pathway terms are demonstrated in [Fig. 4](#f4-etm-0-0-7619){ref-type="fig"}. The data indicated that these enriched genes were involved in matrix formation, activation of matrix metalloproteinase enzymes, ECM organisation, degradation of the ECM, ECM proteoglycan formation, non-integrin membrane-ECM interactions and ECM-receptor interaction. The data suggested that the DEGs primarily participated in the regulation of the ECM.

### PPI network construction and module analysis

The PPI network of the DEGs was constructed according to the STRING database and subsequently visualized and analysed using Cytoscape. The results indicated that 163 genes, including 133 upregulated and 30 downregulated genes, of the 229 DEGs were filtered into the PPI network, and the PPI network complex contained 163 nodes and 438 edges ([Fig. 5](#f5-etm-0-0-7619){ref-type="fig"}). Among the 163 nodes, 24 hub genes were identified with the following filter: Node degree \>10. The top 10 most significant hub genes were albumin, epidermal growth factor, matrix metalloproteinase (*MMP*) 9, collagen type I α 2 chain (*COL1A2*), fibronectin 1, collagen type I α 1 chain (*COL1A1*), collagen type III α 1 chain (*COL3A1*), tissue inhibitors of metalloproteinases 1 (*TIMP1*), integrin subunit α 2 and *MMP2*. Subsequently, MCODE was used to determine the role of the hub genes, and the top 2 significant modules were selected for subsequent analysis. Module 1 consisted of 10 genes, whereas module 2 consisted of 7 genes. GO analysis indicated that module 1 was primarily associated with ECM disassembly and ECM formation, whereas module 2 was primarily associated with ECM organisation and ECM formation ([Table III](#tIII-etm-0-0-7619){ref-type="table"}). Furthermore, pathway enrichment analysis demonstrated that module 1 was mainly enriched in the activation of matrix and the degradation of the ECM, whereas module 2 was mainly enriched in ECM proteoglycan formation, ECM-receptor interaction and ECM organisation ([Table IV](#tIV-etm-0-0-7619){ref-type="table"}). These data indicated that the hub genes served key roles in the regulation of the ECM.

Discussion
==========

Pancreatic cancer is usually asymptomatic and is diagnosed in the advanced stages of progression due to lack of specific and sensitive detection markers that may be used during the early stages of the disease ([@b12-etm-0-0-7619]). The cancer cells are able to readily invade blood vessels and lymph nodes and metastasize to distant organs ([@b13-etm-0-0-7619]). Furthermore, pancreatic cancer is often resistant to conventional treatment, and it is characterised as one of the most lethal neoplasms ([@b14-etm-0-0-7619]). Previously, numerous studies have been performed to explore the underlying mechanism of pancreatic cancer progression and its treatment resistance. However, the disease prognosis has not changed significantly ([@b15-etm-0-0-7619]). The majority of these studies have focused on a single gene to investigate its potential role in pancreatic cancer, although cancer is a complex disease, and is not determined by only one or a few genes.

Therefore, the present study integrated three pancreatic cancer microarray datasets from different studies, using bioinformatics analysis. Consequently, 226 DEGs were identified, which included 176 upregulated and 47 downregulated genes. The function and pathway enrichment analysis were conducted, and the results indicated that these genes primarily participated in the ECM process. Furthermore, a PPI network was constructed in order to determine the role of the hub genes, and MCODE was used to determine the interactions of these genes with several pathways. The results identified 24 hub genes among the 226 DEGs that were associated with ECM regulation.

The ECM is a 3-dimensional non-cellular structure, which serves important roles in all tissues and biological process and is primarily responsible for the maintenance of tissue homeostasis and the regulation of development ([@b16-etm-0-0-7619]). As a complex network, the ECM consists of extracellular macromolecules, including glycoproteins, collagen and enzymes, which provide structural support to the surrounding cells and segregate cells from one another. This sequesters a variety of cellular growth factors and regulates intercellular communication ([@b17-etm-0-0-7619],[@b18-etm-0-0-7619]). Although the composition of the ECM varies between tissues and species, its common functions comprise cell differentiation, cell adhesion and cell to cell communication ([@b19-etm-0-0-7619]). Stem cells are able to actively detect the elasticity and rigidity of the surrounding ECM, and subsequently adjust gene expression, which determines the differentiation process ([@b20-etm-0-0-7619]). Cells bind to the ECM via intermediate actin filaments, which is regulated by specific cell adhesion molecules, including integrin, fibronectin and laminin ([@b21-etm-0-0-7619]). The ECM interacts biochemically with the surrounding cells by serving as a ligand to transmit signals, which mediate cell adhesion, differentiation, apoptosis, survival, proliferation and migration ([@b22-etm-0-0-7619]).

Although the ECM is responsible for regulating normal tissue development and homeostasis, its dysregulation also contributes to neoplastic progression. The development of cancer is significantly affected by the microenvironment and the ECM is considered the major component of tumor associated microenvironment ([@b23-etm-0-0-7619]). Although ECM remodelling is strictly regulated and mediated by the activities of specific enzymes, the dysregulation of these activities may account for the progression and development of certain disease conditions. This may lead to changes in the amount and composition of the ECM, which may significantly alter the biochemical properties of the ECM and promote the oncogenic effects of various pathways, and deregulate cell behaviours during malignant transformation ([@b24-etm-0-0-7619]). Several studies have suggested that the ECM is important for the maintenance of the polarity and architecture of tissues, and that deregulated ECM promotes epithelial-mesenchymal transition, eventually facilitating tumor invasion ([@b25-etm-0-0-7619]). Furthermore, the abnormal ECM function may promote tumor angiogenesis and lymphangiogenesis ([@b26-etm-0-0-7619]) and tumor-associated inflammation ([@b27-etm-0-0-7619]). In summary, abnormal ECM may promote tumor progression through a number of mechanisms.

The present study revealed that the specific DEGs identified primarily participated in ECM formation, as demonstrated by analysis of specific hub genes, including *MMP2, MMP9, TIMP1, COL1A2, COL1A1* and *COL3A1*. MMPs are the primary enzymes that degrade the ECM and are synthesized by tumor cells (MMP7) or tumor stromal cells (MMP2 and MMP9). A previous study has demonstrated that MMPs serves important roles in cancer progression by increasing tumor cell migration, invasion, metastasis and angiogenesis ([@b28-etm-0-0-7619]). In pancreatic cancer, MMPs were correlated with prognosis, survival time, local invasion and distant metastasis ([@b29-etm-0-0-7619]). TIMPs are the endogenous inhibitors of MMPs, which bind to active and alternative sites of the activated MMP enzymes, prevent angiostatin and endostatin production, and serve a role in the promotion of tumor angiogenesis ([@b30-etm-0-0-7619]). The balance between MMPs and TIMPs may determine the ECM dynamics and affect tumor progression ([@b31-etm-0-0-7619]). *COL1A1, COL1A2* and *COL3A1* are the genes that encode collagen proteins, and the target genes of transforming growth factor-β (TGF-β)/SMAD3. Collagens mediate the tumor metastatic process via the interactions with MMPs and may also serve significant roles in the immune response to cancer ([@b32-etm-0-0-7619]). β-TGF/SMAD3 may promote the expression of ECM-associated proteins ([@b33-etm-0-0-7619]). The aforementioned hub genes participated in ECM formation and may serve as potential targets for the treatment of pancreatic cancer.
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###### 

Identification of DEGs. A total of 226 DEGs were identified, including 179 upregulated genes and 47 downregulated genes.

  DEGs            Gene names
  --------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Upregulated     ABHD17C, ACSL5, ADAM28, ADAM9, ADAMTS12, ADGRF1, AEBP1, AGR2, AHNAK2, AK4, ANKRD22, ANLN, ANO1, ANTXR1, ANXA10, ANXA3, ANXA8, APOL1, AREG, ARNTL2, ASAP2, ASPM, BGN, CAPG, CCL18, CCL20, CD109, CDH11, CDH3, CEACAM1, CEACAM5, CEACAM6, CEMIP, CLDN18, COL10A1, COL11A1, COL12A1, COL1A1, COL1A2, COL3A1, COL5A2, COL8A1, COMP, CORIN, CP, CST1, CST2, CTHRC1, CTSE, CXCL5, DDX60, DGKH, DHRS9, DKK1, DPCR1, DPYSL3, ECT2, EDIL3, EDNRA, EFNA5, EFNB2, ENO2, EPHA4, EPYC, ERO1A, ESM1, ETV1, FAP, FBXO32, FERMT1, FGD6, FN1, FOXQ1, FXYD3, GABRP, GALNT5, GCNT3, GJB2, GPRC5A, GPX2, GPX8, GREM1, HEPH, HK2, IFI27, IFI44L, IGF2BP3, IGFBP5, IL1R2, INHBA, INPP4B, ITGA2, ITGA3, ITGB4, KCNN4, KRT19, KRT7, KYNU, LAMA3, LAMB3, LAMC2, LCN2, LEF1, LOXL2, LRRN1, MALL, MATN3, MBOAT2, MELK, MET, MICAL2, MLPH, MMP1, MMP11, MMP12, MMP14, MMP7, MMP9, MTMR11, MXRA5, MYOF, NMU, NOX4, NPR3, NQO1, NRP2, NT5E, NTM, OAS1, OAS2, OLR1, OSBPL3, PCDH7, PGM2L1, PKM, PLA2R1, PLAC8, PLAT, PLAU, PLPP4, PLS1, POSTN, RAI14, RHBDL2, RUNX2, S100A16, S100P, SCEL, SCNN1A, SDR16C5, SERPINB3, SERPINB5, SLC22A3, SLC2A1, SLC44A4, SLC6A14, SLC6A6, SLPI, SRPX2, ST6GALNAC1, STYK1, SULF1, SULF2, SULT1C2, SYTL2, TCN1, TFF1, TGFBI, THBS2, TMC5, TMEM45B, TMPRSS4, TNFAIP6, TOP2A, TRIM29, TSPAN1, TSPAN8, VCAN, VSIG1
  Downregulated   ABAT, ACADL, ADAMTS6, ALB, ANPEP, AOX1, BACE1, BNIP3, BTG2, C5, CHRM3, CTNND2, DPP10, EGF, EPB41L4B, EPHX2, ERO1B, F11, F8, FAM129A, FAM150B, FGL1, GATM, GNMT, GP2, GSTA1, HOMER2, IAPP, KIAA1324, LIFR, MCOLN3, MT1G, NR5A2, NUCB2, PAIP2B, PDK4, PNLIPRP1, RBPJL, RGN, SERPINI2, SLC16A10, SLC1A2, SLC39A5, SLC43A1, SLC4A4, TMED6, TRHDE

DEGs, differentially expressed genes.

###### 

Enrichment analysis of DEGs in pancreatic cancer.

  DEGs            Term         Description                                 Category   P-value
  --------------- ------------ ------------------------------------------- ---------- --------------
  Upregulated     GO:0030198   Extracellular matrix organization           BP         8.62×10^−16^
                  GO:0031012   Extracellular matrix                        CC         1.09×10^−14^
                  GO:0007155   Cell adhesion                               BP         2.15×10^−14^
                  GO:0030574   Collagen catabolic process                  BP         6.69×10^−14^
                  GO:0005615   Extracellular space                         CC         3.16×10^−13^
                  GO:0005576   Extracellular region                        CC         3.37×10^−11^
                  GO:0005578   Proteinaceous extracellular matrix          CC         1.11×10^−10^
                  GO:0035987   Endodermal cell differentiation             BP         1.85×10^−10^
                  GO:0070062   Extracellular exosome                       CC         1.37×10^−9^
                  GO:0022617   Extracellular matrix disassembly            BP         4.93×10^−9^
  Downregulated   GO:0070062   Extracellular exosome                       CC         5.19×10^−6^
                  GO:0072593   Reactive oxygen species metabolic process   BP         9.67×10^−5^
                  GO:0006508   Proteolysis                                 BP         1.62×10^−3^
                  GO:0005615   Extracellular space                         CC         5.84×10^−3^
                  GO:0015171   Amino acid transmembrane transporter        MF         6.37×10^−3^
                  GO:0009267   Cellular response to starvation             BP         6.44×10^−3^
                  GO:0005887   Integral component of plasma membrane       CC         8.01×10^−3^
                  GO:0031093   Platelet α granule lumen                    CC         8.50×10^−3^
                  GO:0016323   Basolateral plasma membrane                 CC         1.05×10^−2^
                  GO:0005576   Extracellular region                        CC         1.77×10^−2^

DEGs, differentially expressed genes; CC, cellular component; MF, molecular function; BP, biological process.

###### 

Gene Ontology analysis of the top 2 modules genes.

  Modules    Term         Description                          Category   P-value
  ---------- ------------ ------------------------------------ ---------- --------------
  Module 1   GO:0004252   Serine-type endopeptidase activity   MF         7.34×10^−6^
             GO:0022617   Extracellular matrix disassembly     BP         3.13×10^−5^
             GO:0005576   Extracellular region                 CC         5.57×10^−5^
             GO:0070062   Extracellular exosome                CC         8.66×10^−5^
             GO:0009986   Cell surface                         CC         8.69×10^−5^
             GO:0006508   Proteolysis                          BP         2.14×10^−4^
             GO:0005615   Extracellular space                  CC         3.18×10^−4^
             GO:0031093   Platelet α granule lumen             CC         3.31×10^−4^
             GO:0031012   Extracellular matrix                 CC         5.06×10^−4^
             GO:0030574   Collagen catabolic process           BP         7.34×10^−6^
  Module 2   GO:0001501   Skeletal system development          BP         2.22×10^−10^
             GO:0030198   Extracellular matrix organization    BP         1.22×10^−9^
             GO:0031012   Extracellular matrix                 CC         6.47×10^−9^
             GO:0005615   Extracellular space                  CC         1.61×10^−7^
             GO:0005578   Proteinaceous extracellular matrix   CC         6.70×10^−7^
             GO:0005201   Extracellular matrix structural      MF         1.19×10^−6^
             GO:0007155   Cell adhesion                        BP         7.91×10^−6^
             GO:0005576   Extracellular region                 CC         2.97×10^−5^
             GO:0005518   Collagen binding                     MF         1.85×10^−4^
             GO:0030574   Collagen catabolic process           BP         2.12×10^−4^

CC, cellular component; MF, molecular function; BP, biological process.

###### 

Pathway enrichment analysis of the top 2 module genes.

  Modules    Pathway         Name                                                           P-value
  ---------- --------------- -------------------------------------------------------------- -------------
  Module 1   R-HSA-1592389   Activation of matrix                                           3.63×10^−6^
             R-HSA-1442490   Collagen degradation                                           1.71×10^−3^
             R-HSA-1474228   Degradation of the extracellular                               2.52×10^−3^
             R-HSA-114608    Platelet degranulation                                         6.86×10^−3^
             R-HSA-75205     Dissolution of fibrin clot                                     1.28×10^−2^
             hsa04510        Focal adhesion                                                 2.10×10^−2^
             hsa04810        Regulation of actin cytoskeleton                               2.30×10^−2^
             R-HSA-210991    Basigin interactions                                           2.45×10^−2^
             R-HSA-3000157   Laminin interactions                                           2.94×10^−2^
             R-HSA-2022090   Assembly of collagen fibrils and other multimeric structures   4.47×10^−2^
  Module 2   R-HSA-3000178   ECM proteoglycans                                              2.14×10^−8^
             R-HSA-216083    Integrin cell surface interactions                             8.11×10^−6^
             hsa04512        ECM-receptor interaction                                       1.89×10^−5^
             R-HSA-1474244   Extracellular matrix organization                              2.54×10^−5^
             R-HSA-3000170   Syndecan interactions                                          8.48×10^−5^
             R-HSA-3000171   Non-integrin membrane-ECM                                      1.88×10^−4^
             R-HSA-2022090   Assembly of collagen fibrils and other multimeric structures   2.49×10^−4^
             hsa04510        Focal adhesion                                                 2.50×10^−4^
             R-HSA-1442490   Collagen degradation                                           4.83×10^−4^
             hsa04151        PI3K-Akt signaling pathway                                     1.14×10^−3^

CC, cellular component; MF, molecular function; BP, biological process; ECM, extracellular matrix; hsa, *Homo sapiens*.
